Table 1.
Clinical parameters of the 259 analyzed patients.
| Patients (n) | 259 |
| Age at PBF measurement (years) | 65 ± 13 |
| Female sex (n; %) | 138 (53%) |
| WHO-FC 1/2/3/4 (%) | 4/40/49/7 |
| 6-minute walk distance (m) | 344 ± 113 |
| NTpro-BNP (pg/ml) | 1620 ± 1940 |
| TAPSE (mm) | 18.3 ± 4.9 |
| DLCO (% predicted) | 49 ± 22 |
| Mean PA pressure at PH diagnosis (mmHg) | 42 ± 11 |
| Cardiac output at PH diagnosis (l/min) | 4.9 ± 1.5 |
| Innocor-PBF (l/min) | 4.3 ± 1.3 |
| Time between PH diagnosis and PBF measurement (months) | 9 [0; 36] |
| PAH-Medication w/o CCB (n) | 157 |
| Phosphodiesterase-5-inhibitor (n) | 129 |
| Endothelin-receptor-antagonist (n) | 69 |
| Prostacyclin (n) | 13 |
| Riociguat (n) | 1 |
| PH-monotherapy (n) | 108 |
| PH-dual/triple combination therapy (n) | 43/6 |
| CCB (n) | 47 |
| Anticoagulation | 193 (76%) |
Note: Results are provided as mean ± standard deviation for normally distributed and as median (interquartile range) for non-normally distributed variables.
CCB: calcium channel blocker; DLCO: diffusion capacity of the lung for carbon monoxide; PA: pulmonary artery; PBF: pulmonary blood flow; PH: pulmonary hypertension; TAPSE: tricuspid annular plane systolic excursion; WHO-FC: World Health Organization functional class.